EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3

Clémence Vacher, Julia Dubois iD, Marie-Eve Hamelin iD, Guy Boivin, Manuel Rosa-Calatrava iD

Reviews in Medical Virology · 2025-11 · 35 (6)

DOI: 10.1002/rmv.70071 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, online erschienen am 09.10.2025. Verfasst von Clémence Vacher und 4 weiteren Autor:innen. Beteiligte Einrichtung: CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Inserm, Université Claude Bernard Lyon 1, CNRS, ENS de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Parainfluenza Virus 3, Human, Respirovirus Infections, Parainfluenza Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human parainfluenza virus‐type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly. To date, no vaccines nor antiviral drugs have been approved against HPIV3, despite its significant burden in vulnerable people. In this review, we present both past and current prophylactic strategies against HPIV3, such as live‐attenuated virus, vector‐based, subunit and mRNA vaccine candidates or antibody‐based passive protection. For each strategy, we give an overview of the most promising candidates evaluated in preclinical studies and we report immunogenicity and protection data from clinical trials. Finally, we discuss the most important challenges regarding those vaccine strategies and their potential administration to the different vulnerable populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parainfluenza Virus 3, HumanRespirovirus InfectionsParainfluenza VaccinesHumansAnimalsVaccines, AttenuatedClinical Trials as TopicAntibodies, Viral

Stichwörter der Autor:innen

monoclonal antibodiesparainfluenza virus type 3respiratory infectionsvaccine candidates

Substanzen

Vaccines, AttenuatedParainfluenza VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Inserm, Université Claude Bernard Lyon 1, CNRS, ENS de Lyon, Lyon, France.
  • Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec and Université Laval, Québec, QC, Canada.
  • International Research Laboratory RESPIVIR France - Canada, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.
  • Centre International de Recherche en Infectiologie, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, INSERM, CNRS, ENS de Lyon, Lyon, France.
  • Virnext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Lyon, France.

ORCID-Profile: Julia Dubois, Marie-Eve Hamelin, Manuel Rosa-Calatrava

Förderung

  • CIHR

Zitieren

APA

Vacher, C., Dubois, J., Hamelin, M. E., Boivin, G., & Rosa-Calatrava, M. (2025). Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. Reviews in Medical Virology, 35(6). https://doi.org/10.1002/rmv.70071

Vancouver

Vacher C, Dubois J, Hamelin ME, Boivin G, Rosa-Calatrava M. Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. Reviews in Medical Virology. 2025;35(6). doi:10.1002/rmv.70071

BibTeX
@article{Vacher2025,
  author = {Vacher, Clémence and Dubois, Julia and Hamelin, Marie-Eve and Boivin, Guy and Rosa-Calatrava, Manuel},
  title = {Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3},
  journal = {Reviews in Medical Virology},
  year = {2025},
  volume = {35},
  number = {6},
  doi = {10.1002/rmv.70071}
}
Kostenlos starten →